These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20089981)

  • 1. Interleukin-2 therapy in patients with HIV infection.
    Sellier P; Lafuente-Lafuente C; Bergmann JF
    N Engl J Med; 2010 Jan; 362(3):270-1; author reply 271. PubMed ID: 20089981
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin-2 therapy in patients with HIV infection.
    ; ; Abrams D; Lévy Y; Losso MH; Babiker A; Collins G; Cooper DA; Darbyshire J; Emery S; Fox L; Gordin F; Lane HC; Lundgren JD; Mitsuyasu R; Neaton JD; Phillips A; Routy JP; Tambussi G; Wentworth D
    N Engl J Med; 2009 Oct; 361(16):1548-59. PubMed ID: 19828532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-2 immunotherapy does not benefit patients taking antiretrovirals.
    AIDS Patient Care STDS; 2009 Mar; 23(3):221-2. PubMed ID: 19866543
    [No Abstract]   [Full Text] [Related]  

  • 4. IL-2 therapy provides no clinical benefit to HIV-infected patients on ART.
    Clin Infect Dis; 2009 Apr; 48(8):iii. PubMed ID: 19301459
    [No Abstract]   [Full Text] [Related]  

  • 5. Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study.
    Ledergerber B; Cavassini M; Battegay M; Bernasconi E; Vernazza P; Hirschel B; Furrer H; Rickenbach M; Weber R;
    HIV Med; 2011 May; 12(5):279-88. PubMed ID: 20955356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial treatment of HIV-1 infection.
    Nicastri E; Narciso P; Andreoni M
    N Engl J Med; 2008 Aug; 359(9):970-1; author reply 971. PubMed ID: 18763319
    [No Abstract]   [Full Text] [Related]  

  • 7. Co-trimoxazole, cART, and non-AIDS infectious diseases.
    Anglaret X; Eholie S
    Lancet; 2010 Apr; 375(9722):1231-3. PubMed ID: 20347482
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of interleukin-2 in patients with HIV infection.
    Pett SL; Kelleher AD; Emery S
    Drugs; 2010 Jun; 70(9):1115-30. PubMed ID: 20518579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Simultaneous treatment of HIV and tuberculosis is possible and necessary].
    von der Maase S; Gerstoft J; Wejse C
    Ugeskr Laeger; 2014 Feb; 176(6A):V03130163. PubMed ID: 25347439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DART points the way for HIV treatment programmes.
    Phillips A; van Oosterhout J
    Lancet; 2010 Jan; 375(9709):96-8. PubMed ID: 20004465
    [No Abstract]   [Full Text] [Related]  

  • 12. Aldesleukin therapy in HIV-infected patients.
    Sundin DJ; Wolin MJ
    Am J Health Syst Pharm; 1998 Jul; 55(14):1520-3. PubMed ID: 9676300
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).
    Kilby JM; Bucy RP; Mildvan D; Fischl M; Santana-Bagur J; Lennox J; Pilcher C; Zolopa A; Lawrence J; Pollard RB; Habib RE; Sahner D; Fox L; Aga E; Bosch RJ; Mitsuyasu R;
    J Infect Dis; 2006 Dec; 194(12):1672-6. PubMed ID: 17109338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 2 treatment for HIV infection.
    Blankson J; Siliciano RF
    JAMA; 2000 Jul; 284(2):236-8. PubMed ID: 10889599
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of HIV viral load, CD4 cell count and antiretroviral therapy on human papillomavirus prevalence in urine samples of HIV-infected men.
    Jong E; van Gorp EC; Mulder JW; Tol A; Smits PH
    Int J STD AIDS; 2009 Apr; 20(4):262-4. PubMed ID: 19304972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV.
    Guiguet M; Furco A; Tattevin P; Costagliola D; Molina JM;
    HIV Med; 2007 Mar; 8(2):124-30. PubMed ID: 17352769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2.
    Markowitz N; Bebchuk JD; Abrams DI;
    Clin Infect Dis; 2003 Oct; 37(8):e115-20. PubMed ID: 14523786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
    Kovacs JA; Vogel S; Albert JM; Falloon J; Davey RT; Walker RE; Polis MA; Spooner K; Metcalf JA; Baseler M; Fyfe G; Lane HC
    N Engl J Med; 1996 Oct; 335(18):1350-6. PubMed ID: 8857018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 (IL-2, Proleukin) and immune function.
    Proj Inf Perspect; 2003 Jan; (35):16. PubMed ID: 12647677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnitude of opportunistic diseases and their predictors among adult people living with HIV enrolled in care: national level cross sectional study, Ethiopia.
    Weldegebreal T; Ahmed I; Muhiye A; Belete S; Bekele A; Kaba M
    BMC Public Health; 2018 Jul; 18(1):820. PubMed ID: 29970047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.